{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:35:05Z","timestamp":1794900905819,"version":"4.9.1"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>mTOR is a highly conserved serine\/threonine protein kinase that serves as a central regulator of cell growth, survival, and autophagy. Deregulation of the PI3K\/Akt\/mTOR signaling pathway occurs commonly in cancer and numerous inhibitors targeting the ATP-binding site of these kinases are currently undergoing clinical evaluation. Here, we report the characterization of Torin2, a second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. Torin2 inhibited mTORC1-dependent T389 phosphorylation on S6K (RPS6KB1) with an EC50 of 250 pmol\/L with approximately 800-fold selectivity for cellular mTOR versus phosphoinositide 3-kinase (PI3K). Torin2 also exhibited potent biochemical and cellular activity against phosphatidylinositol-3 kinase\u2013like kinase (PIKK) family kinases including ATM (EC50, 28 nmol\/L), ATR (EC50, 35 nmol\/L), and DNA-PK (EC50, 118 nmol\/L; PRKDC), the inhibition of which sensitized cells to Irradiation. Similar to the earlier generation compound Torin1 and in contrast to other reported mTOR inhibitors, Torin2 inhibited mTOR kinase and mTORC1 signaling activities in a sustained manner suggestive of a slow dissociation from the kinase. Cancer cell treatment with Torin2 for 24 hours resulted in a prolonged block in negative feedback and consequent T308 phosphorylation on Akt. These effects were associated with strong growth inhibition in vitro. Single-agent treatment with Torin2 in vivo did not yield significant efficacy against KRAS-driven lung tumors, but the combination of Torin2 with mitogen-activated protein\/extracellular signal\u2013regulated kinase (MEK) inhibitor AZD6244 yielded a significant growth inhibition. Taken together, our findings establish Torin2 as a strong candidate for clinical evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic role. Cancer Res; 73(8); 2574\u201386. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-12-1702","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T07:41:18Z","timestamp":1361605278000},"page":"2574-2586","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR"],"prefix":"10.1158","volume":"73","author":[{"given":"Qingsong","family":"Liu","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivapriya","family":"Kirubakaran","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooyoung","family":"Hur","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Westover","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Ercan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Niepel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson C.","family":"Thoreen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong A.","family":"Kang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Patricelli","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Tupper","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Altabef","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn D.","family":"Held","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Chou","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Elledge","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"Janne","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Sabatini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology; 3Departments of Medicine and Medical Oncology, Ludwig Center at Dana-Farber\u2013Harvard Cancer Center; 4Lowe Center for Thoracic Oncology; 5Lurie Family Imaging Center, Dana-Farber Cancer Institute; 6Division of Genetics, Howard Hughes Medical Institute; 7Department of Medicine, Brigham and Women's Hospital; 8Department of Radiation Oncology, Massachusetts General Hospital; Departments of 9Biological Chemistry and Molecular Pharmacology and 10Genetics, 11Center for Cell Decision Processes, Department of Systems Biology, Harvard Medical School; 12Harvard Radiation Oncology Program, Boston; 13Whitehead Institute for Biomedical Research; 14Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; 15Koch Center for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts; and 16ActivX Biosciences, Inc., La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,4,15]]},"reference":[{"key":"2022061704060044600_bib1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"2022061704060044600_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.dnarep.2004.04.002","article-title":"PI 3-kinase related kinases: \u2018big\u2019 players in stress-induced signaling pathways","volume":"3","author":"Abraham","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"2022061704060044600_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"2022061704060044600_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061704060044600_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2022061704060044600_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"2022061704060044600_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061704060044600_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"2022061704060044600_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"2022061704060044600_bib10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"2022061704060044600_bib11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2022061704060044600_bib12","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J Biol Chem"},{"key":"2022061704060044600_bib13","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1021\/jm101144f","article-title":"Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer","volume":"53","author":"Liu","year":"2010","journal-title":"J Med Chem"},{"key":"2022061704060044600_bib14","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"2022061704060044600_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0014-5793(98)00043-X","article-title":"G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells","volume":"422","author":"Casagrande","year":"1998","journal-title":"FEBS Lett"},{"key":"2022061704060044600_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-07-0669","article-title":"A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity","volume":"68","author":"Garlich","year":"2008","journal-title":"Cancer Res"},{"key":"2022061704060044600_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"2022061704060044600_bib18","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res"},{"key":"2022061704060044600_bib19","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"2022061704060044600_bib20","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061704060044600_bib21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022061704060044600_bib22","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.bmcl.2010.07.104","article-title":"PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) inhibitor","volume":"20","author":"Venkatesan","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2022061704060044600_bib23","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","volume":"69","author":"Yu","year":"2009","journal-title":"Cancer Res"},{"key":"2022061704060044600_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)","volume":"421","author":"Garcia-Martinez","year":"2009","journal-title":"Biochem J."},{"key":"2022061704060044600_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704060044600_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704060044600_bib27","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"Garcia-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061704060044600_bib28","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin","volume":"10","author":"Bhagwat","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022061704060044600_bib29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J Med Chem"},{"key":"2022061704060044600_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chembiol.2011.04.011","article-title":"In situ kinase profiling reveals functionally relevant properties of native kinases","volume":"18","author":"Patricelli","year":"2011","journal-title":"Chem Biol"},{"key":"2022061704060044600_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/bi062142x","article-title":"Functional interrogation of the kinome using nucleotide acyl phosphates","volume":"46","author":"Patricelli","year":"2007","journal-title":"Biochemistry"},{"key":"2022061704060044600_bib32","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.onc.1208439","article-title":"Medium-mediated intercellular communication is involved in bystander responses of X-ray irradiated normal human fibroblasts.","volume":"24","author":"Yang","year":"2005","journal-title":"Oncogene"},{"key":"2022061704060044600_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nmeth.1600","article-title":"Adaptive informatics for multifactorial and high-content biological data","volume":"8","author":"Millard","year":"2011","journal-title":"Nat Methods"},{"key":"2022061704060044600_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/bioinformatics\/btp667","article-title":"DataPflex: a MATLAB-based tool for the manipulation and visualization of multidimensional datasets","volume":"26","author":"Hendriks","year":"2010","journal-title":"Bioinformatics"},{"key":"2022061704060044600_bib35","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1101\/gad.943001","article-title":"Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras","volume":"15","author":"Jackson","year":"2001","journal-title":"Genes Dev"},{"key":"2022061704060044600_bib36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature06030","article-title":"LKB1 modulates lung cancer differentiation and metastasis","volume":"448","author":"Ji","year":"2007","journal-title":"Nature"},{"key":"2022061704060044600_bib37","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-10-0125","article-title":"A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061704060044600_bib38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature10937","article-title":"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response","volume":"483","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"2022061704060044600_bib39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"2022061704060044600_bib40","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1074\/jbc.M111.304485","article-title":"Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics","volume":"287","author":"Liu","year":"2012","journal-title":"J Biol Chem"},{"key":"2022061704060044600_bib41","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061704060044600_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"key":"2022061704060044600_bib43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"key":"2022061704060044600_bib44","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J Clin Invest"},{"key":"2022061704060044600_bib45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2022061704060044600_bib46","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat Med"},{"key":"2022061704060044600_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccr.2007.06.005","article-title":"Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"key":"2022061704060044600_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/8\/2574\/2695067\/2574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/8\/2574\/2695067\/2574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:18:15Z","timestamp":1655461095000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/8\/2574\/587201\/Characterization-of-Torin2-an-ATP-Competitive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,15]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,4,15]]},"published-print":{"date-parts":[[2013,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-12-1702","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6505128","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6505128.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22398726.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398729.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398723","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398723.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398729","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.718400680.793522102","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,15]]}}}